Resource Logo

Antibodies to Butyrate inducible antigens of Kaposi's sarcoma-associated herpesvirus (KSHV) in (HIV-1) infected patients.


3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:165. Unique

Objectives: 1) To identify a serologic marker of infection with a novel herpesvirus putatively associated with Kaposi's sarcoma (KS) and 2) to determine the prevalence of KSHV infection as defined by serology in HIV-infected patients with and without KS. Methods: KSHV antigens were prepared from a cell-line, BC-1, provided by Moore and Chang. Immunoblot and immunofluorescence assays were used to examine sera for evidence of antibody production to viral antigens. Results: Treatment of BC-1 cells with n-butyrate selectively triggered expression of new antigenic KSHV-associated polypeptides that were recognized by sera from patients with KS. Antibodies to a unique 40 kDa protein (p4O) from chemically induced BC-1 cells were present in 67% of 48 KS patients compared to 13% of 54 HIV-infected patients without KS (OR=13.43, 95% CI=4.48-42.0). The positive predictive value of the serologic test for KS was 82%. Imunofluorescence and immunoblot results were very closely correlated. Conclusion: The presence of antibodies to an inducible antigen was strongly correlated with clincally evident KS in HIV-infected subjects. The serologic results support the hypothesis of an etiologic role for KSHV.

Acquired Immunodeficiency Syndrome/COMPLICATIONS/*IMMUNOLOGY Antigens, Viral/*BIOSYNTHESIS Butyrates/*PHARMACOLOGY Cell Line Herpesviridae/*IMMUNOLOGY Herpesviridae Infections/*COMPLICATIONS/EPIDEMIOLOGY Human Prevalence Sarcoma, Kaposi's/COMPLICATIONS/*IMMUNOLOGY ABSTRACT


Information in this article was accurate in November 30, 1996. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.